Literature DB >> 2659100

Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantation.

G L Phillips1, S N Wolff, R H Herzig, H M Lazarus, J W Fay, H S Lin, D C Shina, G P Glasgow, R C Griffith, C W Lamb.   

Abstract

Twenty-six patients with progressive Hodgkin's disease after conventional chemotherapy received intensive chemoradiotherapy and autologous bone marrow transplantation (ABMT); 19 also received additional involved-field radiotherapy. Twenty-one patients [81%, 95% confidence intervals (CI) 61% to 94%] attained complete (n = 18) or partial responses. Ten patients (38%, 95% CI 20% to 59%) are disease-free a median of 4.5 years later (range 3.5 to 7.0 years), including seven patients with continuous complete responses. The likelihood of overall response was not significantly influenced by any clinical or treatment variable examined. However, there was a trend favoring patients with higher Karnofsky scores, and higher scores were associated with attainment of complete responses (P = .06 and P = .02, respectively, Mann-Whitney U test). Both higher Karnofsky scores and shorter durations of disease before transplantation were associated with improved survival in a stepwise Cox multivariate analysis. The chief cause of failure was progression at sites previously involved with Hodgkin's disease. No patient relapsed in the marrow, and two of three patients with a history of marrow involvement with Hodgkin's disease achieved durable complete responses after transplantation. These data suggest that inadequate pretransplant conditioning, and not the reinoculation of occult tumor cells in the autologous marrow, caused most relapses. Fatal treatment-related toxicity occurred in six patients. Three patients died of idiopathic interstitial pneumonitis; each had previously received local mediastinal irradiation before intensive chemoradiotherapy. Intensive chemoradiotherapy and ABMT produces durable responses in some patients with Hodgkin's disease incurable with conventional therapy. Use of such therapies at the first sign of failure with conventional chemotherapy and development of more effective conditioning regimens should further improve results.

Entities:  

Mesh:

Year:  1989        PMID: 2659100

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

Review 1.  Changing role and decreasing size: current trends in radiotherapy for Hodgkin's disease.

Authors:  Joachim Yahalom
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

2.  High-dose etoposide: from phase I to a component of curative therapy.

Authors:  Steven N Wolff; John D Hainsworth; F Anthony Greco
Journal:  J Clin Oncol       Date:  2008-10-06       Impact factor: 44.544

3.  Granulocyte colony-stimulating factor (G-CSF) treatment in a neutropenic leukemia patient with diffuse interstitial pulmonary infiltrates.

Authors:  A Heyll; C Aul; F Gogolin; M Thomas; M Arning; A Gehrt; U Hadding
Journal:  Ann Hematol       Date:  1991-12       Impact factor: 3.673

Review 4.  Refractory and relapsing Hodgkin's disease: role of high-dose chemotherapy with bone marrow transplantation.

Authors:  M Thomas; N Gattermann; W Schneider
Journal:  Klin Wochenschr       Date:  1990-06-05

5.  A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.

Authors:  Sarah A Milgrom; Shekeab Jauhari; John P Plastaras; Yago Nieto; Bouthaina S Dabaja; Chelsea C Pinnix; Grace L Smith; Pamela K Allen; J Nicholas Lukens; Amit Maity; Yasuhiro Oki; Michelle A Fanale; Sunita D Nasta
Journal:  Cancer       Date:  2016-12-16       Impact factor: 6.860

Review 6.  The role of autografting in lymphoma.

Authors:  D W Milligan; S G Long
Journal:  Postgrad Med J       Date:  1994-07       Impact factor: 2.401

Review 7.  Allogeneic hematopoietic stem cell transplantation: does it have a place in treating Hodgkin lymphoma?

Authors:  Rachel B Salit; Michael R Bishop; Steven Z Pavletic
Journal:  Curr Hematol Malig Rep       Date:  2010-10       Impact factor: 3.952

Review 8.  High-Dose Chemotherapy and Autologous Stem Cell Transplant in Older Patients with Lymphoma.

Authors:  Oscar B Lahoud; Craig S Sauter; Paul A Hamlin; Parastoo Bahrami Dahi
Journal:  Curr Oncol Rep       Date:  2015-09       Impact factor: 5.075

9.  High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease.

Authors:  N Schmitz; B Glass; P Dreger; T Haferlach; H A Horst; J Ollech-Chwoyka; M Suttorp; W Gassmann; H Löffler
Journal:  Ann Hematol       Date:  1993-05       Impact factor: 3.673

10.  Incidence and outcome of overt gastrointestinal bleeding in patients undergoing bone marrow transplantation.

Authors:  S Kaur; G Cooper; S Fakult; H M Lazarus
Journal:  Dig Dis Sci       Date:  1996-03       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.